Work

Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors

Year: 2006

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.24.18_suppl.3017

Authors: H. Van Cruijsen, E. E. Voest, C. M. Van Herpen, K. Hoekman, P. O. Witteveen, M. L. Tjin-A-ton, C. J. Punt, T. Puchalski, T. Milenkova, G. Giaccone

Institutions: Radboud University Medical Center, University Medical Center Utrecht

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2228204672

Cites:

Cited by: 15

Related to: 10